TAILIEUCHUNG - Chapter 065. Gene Therapy in Clinical Medicine (Part 5)

Other Diseases The power and versatility of gene transfer approaches are such that there are few serious disease entities for which gene transfer therapies are not under development. Besides those already discussed, other areas of interest include gene therapies for HIV and for neurodegenerative disorders. The latter include studies in patients with Parkinson's disease, where AAV vectors expressing enzymes required for enhanced production of dopamine, or of the inhibitory neurotransmitter γ-aminobutyric acid, have been introduced into affected areas of the brain (striatum, subthalamic nucleus) by stereotactic neurosurgery. In Alzheimer's disease, an ex vivo approach in which autologous fibroblasts are transduced. | Chapter 065. Gene Therapy in Clinical Medicine Part 5 Other Diseases The power and versatility of gene transfer approaches are such that there are few serious disease entities for which gene transfer therapies are not under development. Besides those already discussed other areas of interest include gene therapies for HIV and for neurodegenerative disorders. The latter include studies in patients with Parkinson s disease where AAV vectors expressing enzymes required for enhanced production of dopamine or of the inhibitory neurotransmitter y-aminobutyric acid have been introduced into affected areas of the brain striatum subthalamic nucleus by stereotactic neurosurgery. In Alzheimer s disease an ex vivo approach in which autologous fibroblasts are transduced with a retroviral vector expressing nerve growth factor then reimplanted into the basal forebrain has slowed the rate of cognitive decline in a small Phase I study. Summary The development of new classes of therapeutics typically takes two to three decades monoclonal antibodies and recombinant proteins are recent examples. Gene therapeutics which entered clinical testing in the early 1990s are well along in the course of development and are likely to become increasingly important as a therapeutic modality in the twenty-first century. A central question to be addressed is the long-term safety of gene transfer and regulatory agencies have mandated a 15-year follow-up for subjects enrolled in gene therapy trials Table 65-3 . Realization of the therapeutic benefits of the Human Genome Project and of new discoveries such as RNAi will depend on continued progress in gene transfer technology. Table 65-3 Taking History from Subjects Enrolled in Gene Transfer Studies Elements of History for Subjects Enrolled in Gene Transfer Trials 1. What vector was administered Is it predominantly integrating retroviral lentiviral herpesvirus latency and reactivation or non-integrating plasmid adenoviral AAV 2. What was the route of .

• Y học thường thức
• Gene Therapy
• Clinical Medicine
• bệnh học và điều trị
• bài giảng bệnh học
• tài liệu y khoa
• Harrisons Internal Medicine
• Transgene Expression
• Uptake Mechanism
• Gene Delivery
• Polylipid Nanoparticle
• Mesenchymal stem cells
• Baculoviral vector
• Cancer gene therapy
• Green fluorescence protein
• BMC Cancer
• Genetically engineered mesenchymal stromal cells
• Cell therapy
• Suicide gene therapy
• Clinical trial
• Clostridium perfringens enterotoxin
• Colon cancer
• Suicide gene
• Bladder cancer
• Radical cystectomy
• Perioperative chemotherapy
• Perioperative targeted therapy
• Immune therapy
• trình bày báo cáo
• tài liệu báo cáo khoa học
• nghiên cứu y học
• báo cáo y học
• kiến thức y học
• Novel
• Gene
• Therapy
• Approaches
• Ming Wei
• David Good
• Dermal fibroblast
• Nucleofection method
• Green fluorescent protein
• Clinical gene therapy
• Fetal Calf Serum
• Adeno associated viral vector
• Chicken beta actin promoter
• Heparan sulfate proteoglycans
• Red fluorescent protein
• Gene transfer techniques
• Hepatocellular carcinoma
• Combined therapy
• VX2 tumor
• Tumor gene therapy
• Thymidine kinase
• Directly targeting
• Bifidobacterial recombinant thymidine kinase
• Targeting system
• Antitumor mechanisms
• Artificial microRNA
• DNA polymerase
• Caspase 3
• Human sodium iodide symporter
• Radioiodine gene therapy
• Adenine nucleotide translocase 2
• Short hairpin RNA
• Radiation induced immune response
• BMC Bioinformatics
• Patient derived xenograft model
• Gene expression
• Predictive cancer biomarker
• Targeted therapy
• Drug response prediction
• Viral insertion
• Viral integration
• Sequence mapping
• Genome viewer
• BMC Molecular and Cell Biology
• Retinal neovascularization
• Endothelial progenitor cells
• Endostatin transfected EPCs
• BMC Musculoskeletal Disorders
• Endothelial mesenchymal transition
• Mouse aortic endothelial cells
• Endothelial cell targeting property
• Colorectal cancer
• MEK inhibitor
• Cancer stem cell
• Gene expression signature
• báo cáo khoa học
• báo cáo hóa học
• công trình nghiên cứu về hóa học
• tài liệu về hóa học
• cách trình bày báo cáo